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Introduction: The use of opioids is associated with unwanted adverse
effects, particularly opioid-induced constipation (OIC). The adverse effects
of opioids on gastrointestinal function are mediated by the interaction
with opioid receptors in the gastrointestinal tract. The most common drugs
used for relieving OIC are laxatives, which do not address the opioid
receptor-mediated bowel dysfunction and do not provide sufficient relief.
Areas covered: This paper discusses the role of a combination of prolonged-
release formulation of oxycodone (OX) and naloxone (N) in the prevention
and management of OIC, reporting efficacy and safety outcome of controlled
studies. In a therapeutic area of great unmet need, the combination tablet
of prolonged release of OX and N (PR OXN) could offer patients effective
analgesia, while improving opioid-induced bowel dysfunction.
Expert opinion: PR OXN offers a unique and specific mechanism to control
OIC in patients receiving chronic opioid therapy. This combination has the
potential advantage of preventing OIC, particularly in subgroups of popula-
tion, like elderly or advanced cancer patients. This approach can decrease
the use of laxatives and additional medications, which represent a burden
for patients presenting comorbidities requiring multiple medications.
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1. Introduction
Approximately 20% of European population suffers from chronic pain. The most
frequent causes are osteoarthritis and back pain [1]. While opioids are recognized
as the mainstay of pain management for patients with cancer pain, they are also
being increasingly used for the treatment of chronic non-cancer pain. However,
the use of opioids is associated with unwanted adverse effects, particularly opioid-
induced constipation (OIC). The adverse effects of opioids on gastrointestinal
function are mediated by the interaction with opioid receptors in the gastrointesti-
nal tract. Endogenous opioids function to coordinate the contractile process under
normal conditions and suppress intestinal motility. Studies in animals and humans
suggest that endogenous opioids inhibit enteric nerve activity and both propulsive
motor and secretory activities [2]. The enteric mu-opioid receptors appear to be
the principal mediator of opioid agonist effects on the gastrointestinal tract.
When an exogen mu-opioid agonist binds to these receptors, the release of various
neurotransmitters is inhibited, interrupting the coordinate rhythmic contractions
required for intestinal motility and reduces mucosal secretions [3]. Different from
many opioid-related adverse effects which occur at the beginning of treatment
and which tend to disappear over time, constipation constantly persists and
may represent a relevant problem during the chronic treatment with opioids [4].
The physical consequences of constipation demand consideration. The majority
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of patients report some degree of negative impact on quality
of life and are more likely to use healthcare resources, miss
work reporting impaired ability to undertake daily activities.
It is particularly challenging to obtain accurate estimates of
the prevalence of constipation because of numerous other
factors that may also induce constipation, particularly in
cancer patients [3].
The most common drugs used for relieving OIC are
laxatives, which act with different mechanisms on the bowel
transit. However, laxatives do not address the mechanisms
of bowel dysfunction mediated by opioid receptors and do
not provide sufficient relief.
In the last decade, there had been an attempt to target the
underlying mechanisms of opioid action in the gastrointes-
tinal tract by antagonizing opioid receptors. The rationale
was based on the local activity on intestinal opioid receptor
and the negligible oral bioavailability of naloxone (N), which
undergo extensive elimination by hepatic first-pass metabo-
lism. The limited systemic availability of N avoids blocking
the desired central analgesic effects of opioids. A number of
pioneer studies have assessed the ability of oral immediate
release N, also showing some evidence for slightly reduced
analgesic efficacy, and intestinal withdrawal symptoms [5].
A prolonged-release formulation could confer additional
benefits ensuring continual antagonism and by reducing the
risk of overburdening the hepatic enzymatic system responsible
for its first-pass metabolism, thus reducing the risk of N being
systematically available with consequent loss of analgesic
efficacy. In a therapeutic area of great unmet need, therefore,
the combination tablet of prolonged release of oxycodone
(OX) and N (PR OXN) could offer patients effective analgesia
while improving opioid-induced bowel dysfunction (see Box 1).
2. Overview of the market
Opioids invariably cause constipation. Although other common
unwanted effects, such as sedation, nausea and vomiting, tend
to improve with continued use and often resolve completely,
OIC does not get better with repeated administration. Laxatives
are commonly used, but their effects do not specifically affect
the cause of constipation. By contrast, drugs with a specific
mechanism, such as antagonismwith intestinal opioid receptors,
may provide a therapeutic effect with a reduce impact of OIC.
Targeted therapies, with a combination of opioids with an
opioid antagonist focusing on the specific mechanism of OIC
may reduce gastrointestinal adverse effects, while maintaining
systemic analgesia. The aim of therapy with PR OXN is to
offer analgesic therapy with an opioid compound like OX
while providing a prevention of constipation, which is one of
the most frequent opioid-related adverse effect, through the
association with N. PR OXN represents a recent and widely
used therapy, approved for the treatment of severe pain which
can be adequately managed only with opioids.
3. Introduction to the compound
PR OXN in a single formulation tablet has been designed
with the intent to prevent or reduce OIC. The coadministra-
tion of OX and N optimal ratio in a fixed ratio of 2:1 did
not significantly alter the bioavailability of either of its con-
stituents [6]. A scintigraphic analysis showed that 20 mg of
OX significantly increased colon arrival time and PR OXN
20/10 mg significantly reduced mean colonic transit time
at values similar to placebo [7]. Two studies provided infor-
mation about the optimal ratio of OX and N to obtain a
significant improvement in bowel transit without influenc-
ing analgesia. To identify the optimal dose ratio of OX
and N, 202 patients with chronic pain receiving stable doses
of PR OX in the range of 40 -- 80 mg/day, were randomized
to receive 10, 20 and 40 mg/day of N or placebo. After a
4-week maintenance phase, patients received OX only for
2 weeks. No loss of analgesic efficacy with N was observed.
Mean pain intensity scores on randomization were compara-
ble to placebo, 10, 20 and 40 mg N dose, and remained
unchanged during treatment. Bowel function improved
with increasing N dose. N in doses of 20 and 40 mg signif-
icantly improved bowel function at the end of the mainte-
nance phase compared with placebo. There was a trend
toward an increased incidence of diarrhea with higher doses
of N. The 2:1 OX:N ratio was identified as the most suitable
for further development [8]. Similarly, to evaluate the
optimal dose ratio for PR OXN, patients with cancer and
non-cancer pain requiring opioid therapy in the range of
40 -- 80 mg of OX, were randomized to receive 10, 20 and
40 mg of N, or placebo every 12 h for 4 weeks. The better
ratio for efficacy and tolerability, as estimated by patients,
was 2:1 [9].
4. Chemistry
The molecular formula of OX and N, in comparison with
morphine is reported in Figure 1.
Box 1. Drug summary.
Drug name PR OXN
Phase III
Indication Prevention of OIC
Pharmacology
description
Association of an opioid analgesic
drug, such as OX, and an opioid
antagonist, such as N, with
negligible systemic reabsorption
Route of
administration
Oral
Chemical structure (5R,9R,13S,14S)-4,5a-epossi-
14-idrossi-3-metossi-17-metilmor-
finan-6-one (C18H21NO4)
Cloridrato di N-allil-4,5a-epossi-3,
14-diidrossi-morfinan-6-one
(C19H21NO4)
Pivotal trial [6]
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5. Pharmacodynamics
OX is a semisynthetic opioid alkaloid structurally similar to
morphine (Figure 1); it acts as full opioid agonist, with affinity
for kappa, mu and delta opiate receptors in the brain, spinal
cord and peripheral organs (e.g., intestine). The clinical
efficacy of OX is similar to that of morphine, but OX is
more potent with an equianalgesic ratio of 1:1.5 -- 2 [10].
N is a competitive antagonist of opioid receptors inside and
outside the central nervous system and, after systemic admin-
istration, it reverses both centrally and peripherally mediated
opioid effects. N is a synthetic opioid antagonist of both cen-
tral and peripheral opioid receptors with a remarkably higher
affinity for mu-, delta- and kappa-receptors than opioid
receptor agonists (Figure 1). Unlike other opioid antagonists,
which do not completely inhibit the analgesic properties of
opioids, N is devoid of any intrinsic agonist activity and
antagonizes all actions of morphine. When administered
intravenously, it acts centrally as a specific antidote in the
management and reversal of overdoses caused by opioid
agents, with a proven long-term safety profile and a safety
over a wide dose range [11].
6. Pharmacokinetics
Oral administration theoretically allows selective blocking of
intestinal opioid receptors without blocking the desired opi-
oid effects, as long as hepatic first-pass capacity is not
exceeded. The low systemic bioavailability due to marked
hepatic first-pass metabolism allows for the low plasma levels
and high enteric wall concentration. After parenteral adminis-
tration, N plasma half life is ~ 1 h; the drug is metabolized in
the liver and excreted in the urine. When orally administered
in tablet form, N undergoes extensive elimination by hepatic
first-pass. As a consequence, the systemic availability is low.
The mean absolute bioavailability of N from the orally
administered PR tablets ranged from 0.9% for the 5 mg
dose to 2% for the 40, 80 and 120 mg doses [12]. Its principal
metabolites are N-glucuronide, 6-Naloxol and its glucuro-
nide [13]. Because of the pronounced first-pass metabolism, a
clinically relevant systemic effect of N after its oral administra-
tion is unlikely; on the other hand, oral N may allow selective
blockade of intestinal opioid receptors. Due to the local
competitive antagonism of the opioid receptor in the gut,
N reduces the bowel function disorders that are typical for
opioid treatment, without blocking the desired analgesic
effects of opioids in the central nervous system [13].
When orally administered, OX is readily absorbed, and its
bioavailability ranges from 60 to 87%, which is higher than
the 20 -- 40% for morphine. OX has an elimination half life
of ~ 3 h and is extensively metabolized in the liver, mainly
via CYP3A4 to the inactive metabolite noroxycodone (47%
of the dose), by 6-keto reduction to the most likely inactive
metabolites, a- and b-oxycodol (8% of the dose), and via
CYP2D6 to the active metabolite oxymorphone (11% of the
dose), which has some analgesic activity but is present in the
plasma in a conjugated form and in low concentrations.
Thus, the parent drug exerts the major central opioid effects,
with negligible contribution from its circulating oxidative and
reductive metabolites. OX and its metabolites are excreted in
the urine [10].
PR OXN is a prolonged-release fixed combination. The
release of OX from PR formulation tablets is biphasic with an
initial relatively fast release providing an early onset of analgesia,
followed by a more controlled release which determines the 12 h
duration of action. The mean apparent elimination half life of
PR OX is 4.5 h, which leads to steady-state being achieved in
about 1 day. The mean absolute bioavailability of N from orally
administered PR tablets was found to be very low, ranging from
0.9% for the 5 mg dose to 2% for the 40, 80 and 120 mg doses,
based on area under the concentration--time curve (AUCt)
values; the pharmacokinetics of N were linear across the range
of oral doses [13]. A study compared pharmacokinetics data
from a single-dose study and a multiple-dose bioequivalence
study of fixed-dose combination PR OXN versus separate
formulations of PR OX and PR N. Both in the single-dose
and multiple-dose steady-state bioequivalence studies, the
mean plasma OX concentration--time curves for PR OX and
PR OXN were similar; there were no statistically significant
differences between the treatments, indicating that the
coadministration of PR OX and PR N in a fixed-dose
combination (PR OXN) would not significantly affect the
bioavailability of either of its constituents [6].
7. Clinical efficacy
Three studies were performed in patients with low back pain
and with chronic pain of different origins. A randomized,
HO
HO
O
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Figure 1. Molecular formulas of morphine, OX and N.
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double-blind, placebo- and active-controlled, parallel-group
study was designed in 463 patients with moderate-to-severe
low back pain. Doses of OX were in the range of
20 -- 40 mg/day. The active control group was included to
compare the analgesic efficacy and bowel function of PR
OXN with PR OX. The analgesic efficacy was measured as
the time from the initial dose of study medication to multiple
pain events, corresponding to inadequate analgesia. The num-
ber of recurrent pain events was significantly longer in the PR
OXN group compared with placebo. PR OXN reduced the
risk of pain events by 42% compared with placebo. The
appearance of pain events was comparable for PR OXN as
against PR OX, confirming that the addition of N to OX in
a combination tablet did not negatively affect analgesic effi-
cacy of the opioid. In constipated patients with high bowel
function index, complete spontaneous bowel movement sig-
nificantly increased with PR OXN and was associated with
lower use of laxative in comparison with PR OX group [14].
In a randomized, double-blind, double-dummy 12-week
trial of 322 patients with chronic non-cancer pain, PR
OXN and PR OX were compared, after a run-in phase with
doses of PR OX ranging 20 -- 50 mg/day. A significant
improvement in bowel function index, less use of laxatives
and complete spontaneous bowel movements were repor-
ted with PR OXN in comparison with PR OX, without
compromising analgesia [15].
In another randomized, double-blind, double-dummy,
parallel-group multicenter study the impact of PR OXN for
patients with OIC having moderate-to-severe, nonmalignant
pain, was assessed. Patients were previously converted to PR
OX and titrated to an effective analgesic dose. A total of
265 patients on a stable PR OX of 60 -- 80 mg/day and
with OIC were included in the full analysis population to
receive PR OXN or PR OX. After 1 week of treatment,
patients receiving PR OXN showed a significant improve-
ment in bowel function compared with those in the PR OX
as measured by bowel function index. After 4 weeks of treat-
ment, patients receiving PR OXN had more complete sponta-
neous bowel movements per week and a lower laxative intake
compared with PR OX patients. Improvements in bowel
function were achieved without loss of analgesic efficacy as
pain intensity scores were comparable among the groups
and consistent for the duration of the study [16].
Only one study was performed in cancer patients. A total of
185 patients were assessed in a randomized, double-blind,
active controlled with PR OX, double-dummy, parallel-
group study [17]. Previous opioid and laxative medications
were stopped and patients were randomized to receive PR
OXN or PR OX during the double-blind, double-dummy
phase. Patients were titrated up to 120 mg/day of PR OXN
or PR OX. OX was available as rescue analgesic drug, and bisa-
codyl as laxative rescue medication. Patients requiring higher
doses than 120 mg/day were withdrawn from the study. After
4 weeks, mean bowel function index was significantly lower
with PR OXN and total laxative intake was 20% lower. The
brief pain inventory short-form scores, the use of analgesic
rescue doses, quality of life, rate of discontinuation as well as
adverse effects were comparable.
8. Pooled analysis
The two randomized 12-week, double-blind, parallel-group,
multicenter studies [14,15] comparing PR OXN and PR OX
alone on symptoms of opioid-induced bowel dysfunction in
patients with moderate-to-severe nonmalignant pain were
prospectively designed to be pooled, and the primary outcome
measure of the pooled analysis was to demonstrate noninfer-
iority in 12-week analgesic efficacy of PR OXN versus PR
OX alone. This pooled analysis demonstrated that during a
12-week period, PR OXN provided analgesia that was as
effective as PR OX alone, as indicated by the noninferiority
of PR OXN versus PR OX in mean pain intensity, and a
low and comparable use of supplemental analgesic medication
in both treatment arms. Of interest, patients receiving PR
OXN demonstrated clinically significant improvements in
OIC, and there was also a significantly reduced use of
laxatives in the first 4 weeks of the study in patients who
received PR OXN compared with those who received PR
OX alone [18].
9. Safety and tolerability
In general, controlled studies have demonstrated that PR
OXN is safe and well tolerated. In the study by Vondrackova
et al. [14], most adverse effects were mild or moderate in inten-
sity and the incidence of severe adverse effects was low. The
most frequent adverse effect leading to discontinuation was
nausea. Severe adverse effects were slightly more frequently
reported in PR OXN group than in PR OX group. In the
study by Simpson et al. [15], the incidence of adverse effects
was similar between the two groups. There were fewer
gastrointestinal adverse effects, including nausea, vomiting,
abdominal pain and dyspepsia in the PR OXN group, and
mean duration of treatment-related diarrhea was slightly
shorter in the PR OXN group. A total of 12 patients (9 in
the PR OXN group and 3 in the PR OX group) experienced
serious adverse effects. Opioid withdrawal was observed in
two patients, one for each group. L€owenstein et al. [16]
reported more adverse effects in the PR OXN group than
the PR OX group. This was attributed to the higher incidence
of abdominal pain, as a consequence of an increase in
gut motility.
In the study of cancer patients [17], the proportion of
patients who experienced adverse effects or severe adverse
events was generally similar for PR OXN and PR OX groups.
10. Open-label extension studies
A 4-week postmarketing surveillance study of more than
7,000 patients with cancer and non-cancer pain receiving
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low doses of PR OXN showed that bowel function and qual-
ity of life markedly improved [19]. In a 4-week study, PR
OXN has been also reported to be effective in about
1,500 patients with neuropathic pain, maintaining normal
bowel function and improving quality of life [20]. In a 1-year
extension study of these two double-blind studies, patients
with chronic pain received 20 -- 120 mg doses of PR OXN.
Results from these open-label extension studies over
12 months of treatment have demonstrated the long-
term efficacy and tolerability of PR OXN in the treatment
of chronic non-cancer pain. Patients experienced clinically rel-
evant improvements in OIC, while receiving effective analge-
sic therapy [21]. Limited data are available in cancer pain. In
the only existing controlled study, PR OXN has been shown
to provide superior bowel function compared with prolonged
release PR OX without compromising analgesic efficacy or
safety. Maximum doses were 120/60 mg/day that is in the
range of opioid requirements of many cancer patients [13].
This data was confirmed in an open-label exploratory study
of cancer patients with OIC who were switched to PR OXN
at a maximum daily dose of 40/20 mg. During a 2-week
period of observation, bowel function index as well as stool
consistency significantly improved. Five patients did not
obtain pain relief at that dose and were switched to other
opioids [22].
11. Regulatory affairs
PR OXN has been launched in Germany in 2006 via an expe-
dited approval procedure. In 2012, it is available in more than
20 countries with proven efficacy and tolerability. Real-
life experience with PR OXN is well documented and thou-
sands of patients have taken advantage from this therapy.
A recent research [23] performed by IMS demonstrated that
in Italy more than 157,000 patients have been treated with
OXN during the period from January 2011 to July 2012.
12. Expert opinion
PR OXN offers a unique and specific mechanism to control
OIC in patients receiving chronic opioid therapy. This
combination has the potential advantage of preventing OIC,
particularly in subgroups of population, like elderly or
advanced cancer patients. This approach can decrease the
use of laxatives and additional medications, which represent
a burden for patients presenting comorbidities requiring
multiple medications.
There is a good evidence that PR OXN is effective in
reducing OIC, while maintaining analgesia in patients with
chronic pain. Traditional controlled studies demonstrated
the efficacy and safety of this combination, with an improve-
ment in bowel function and a substantial reduction in the use
of laxatives. This has been proved by reanalysis of larger data
and long-term studies [24]. Moreover, PR OXN was estimated
to be a cost-effective option for treating patients with severe
nonmalignant pain and OIC. Cost effectiveness of PR OXN
and PR OX was compared in patients with moderate-to-
severe nonmalignant pain and OIC from a cohort model
used data from a Phase III randomized, controlled trial. It cal-
culated the cost difference between treatments by combining
the cost of pain therapy with costs of laxatives and other
resources that were used to manage constipated patients.
SF-36 scores were converted into EQ-5D utility values to cal-
culate the quality-adjusted life year. Direct treatment costs
were slightly higher for patients treated with PR OXN than
for those treated with PR OX, but patients treated with PR
OXN experienced a quality of life gain, and had an incremen-
tal cost-effectiveness ratio considerably below thresholds
commonly applied in the United Kingdom [25].
PR OXN tablets provide equivalent analgesia to that of OX
CR tablets of the same OX dose, with a similar adverse-effect
profile. Adding the N component reduces, but does not
eliminate, the prevalence of constipation. Compared with PR
OX, the number needed to treat (NNT) (for one person using
opioids continuously to avoid constipation) was about 4 for
people with existing OIC (after 4 weeks), and about 14 for
people not selected for constipation symptoms (after 12 weeks).
Areas of uncertainty include efficacy data regarding analgesia
and constipation from 12-week randomized controlled trials.
Longer-term data (up to 52 weeks) are from uncontrolled
trials. The tablets have not been compared with a regimen of
OX and prophylactic laxatives.
As the studies in non-cancer pain are limited to a dose
range of up to 80/40 mg of PR OXN, further research
on higher doses would be recommended [5,6,14-16]. New
strengths have been developed recently, which may allow
for the use of larger doses. Actually, the maximal licensed
daily dose is 80/40 mg/day. Doses were extended up to
120/60 mg/day in cancer patients, without reporting loss
of analgesia [17]. In cancer patients it is often necessary to
use high doses of opioids like OX. In an acute palliative
care unit, about 20% of patients require doses of OX higher
than 240 mg/day [26]. As there are no data about such high
doses with PR OXN, potentially, when opioid requirements
became high, dosage could be rounded by PR OX dosing or
a switch should ultimately take place. These aspects should
be assessed in future studies. New generations of opioid
antagonists are going to be developed in the near future.
Studies are ongoing.
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